Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J7OM
|
|||
| Former ID |
DNC008099
|
|||
| Drug Name |
6-(benzylamino)-9-butyl-9H-purine-2-carbonitrile
|
|||
| Synonyms |
Compound 3{8,12}; 6-(benzylamino)-9-butyl-9H-purine-2-carbonitrile; CHEMBL255079
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H18N6
|
|||
| Canonical SMILES |
CCCCN1C=NC2=C(N=C(N=C21)C#N)NCC3=CC=CC=C3
|
|||
| InChI |
1S/C17H18N6/c1-2-3-9-23-12-20-15-16(21-14(10-18)22-17(15)23)19-11-13-7-5-4-6-8-13/h4-8,12H,2-3,9,11H2,1H3,(H,19,21,22)
|
|||
| InChIKey |
OJVVVZACBFLFEJ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin L (CTSL) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Lysosome | |||
| Phagosome | ||||
| Antigen processing and presentation | ||||
| Proteoglycans in cancer | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | Endosomal/Vacuolar pathway | |||
| Collagen degradation | ||||
| Degradation of the extracellular matrix | ||||
| Trafficking and processing of endosomal TLR | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | Primary Focal Segmental Glomerulosclerosis FSGS | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. J Med Chem. 2008 Feb 14;51(3):545-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.